AmerisourceBergen Selected by Deciphera Pharmaceuticals to Support QINLOCK™
May 26 2020 - 8:30AM
Business Wire
AmerisourceBergen, a global healthcare solutions leader,
announced today that it has been selected by Deciphera
Pharmaceuticals (Deciphera) to support QINLOCK (ripretinib).
AmerisourceBergen is providing a unified commercialization approach
for QINLOCK which was approved by the U.S. Food and Drug
Administration (FDA) on Friday, May 15, 2020. QINLOCK is an orally
administered kinase switch control inhibitor approved for the
treatment of adult patients with advanced gastrointestinal stromal
tumor (GIST) who have received prior treatment with 3 or more
kinase inhibitors, including imatinib.
In the United States, there are an estimated 4,000 to 6,000
cases of GIST, a rare form of cancer, diagnosed annually.1 The
gastrointestinal cancer is characterized by disease-related
symptoms, including vague abdominal pain, early feelings of
fullness, vomiting and fatigue due to anemia.2 About 40-70% of
GISTs are found in the stomach, 20-40% in the small intestine,
5-15% in the colon and rectum, and in rare cases, the esophagus
(<5%).3 QINLOCK is a tyrosine kinase switch control inhibitor
that was engineered to broadly inhibit KIT and PDGFRα mutated
kinases, where genetic mutations or alterations in these kinases
play a crucial role in the biology of these tumors leading to
drug-resistance and disease progression.4
“At AmerisourceBergen, we believe we have a responsibility to
help create healthier futures – for patients and our partners. The
opportunity to work with Deciphera and support the launch of
QINLOCK is the perfect example of how our integrated services work
together to fulfill that purpose,” said Jenny Fallone, Director,
Global Branded & Specialty Sourcing, AmerisourceBergen. “We are
proud that Deciphera selected us to help ensure patients affected
by this rare disease – who have exhausted other treatments – have a
new therapeutic option. By working together, we can accelerate
product performance but, most importantly, increase patient access
to this innovative treatment.”
AmerisourceBergen’s established expertise in supporting rare
disease treatments helps ensure that critical medications are
safely delivered from manufacturers to patients every day.
AmerisourceBergen is supporting QINLOCK through:
- Specialty distribution: ASD Healthcare - one of the
nation’s largest specialty pharmaceutical distributors that
provides services to 95 percent of U.S. hospitals, as well as
specialty pharmacies, outpatient dialysis clinics, hemophilia
treatment centers, home healthcare companies and retail pharmacies
- will support the distribution of QINLOCK to approved hospitals,
specialty pharmacies and government entities. Oncology Supply, also
a part of AmerisourceBergen, provides specialty distribution to
independent oncology practices nationwide and will support the
distribution of QINLOCK to oncology practices and clinics for in
office dispensing.
- GPO contracting for community oncology:
AmerisourceBergen provides GPO contracting, integrated dispensing
solutions and expertise through ION Solutions, the largest
physician service organization and group purchasing organization
specializing in the support of independent, community oncology
practices.
- Third-party logistics: ICS, a pharmaceutical third-party
logistics provider, aims to increase supply chain efficiency and
ensure commercial success for this product. ICS will support
distribution to specialty pharmacies and distributors and provide
full order-to-cash services.
- Dispensing: AmerisourceBergen’s specialty pharmacy US
Bioservices has more than 25 years of experience supporting small
patient populations and is dispensing QINLOCK. The pharmacy also
provides customized clinical care, focused on supporting adherence
and patient outcomes. Physicians may submit prescriptions for this
medication to US Bioservices via phone (877-757-0667), fax
(888-899-0067), ePrescribe or the MyPathpoint Prescriber
Portal.
AmerisourceBergen’s unified approach is supported by world-class
commercialization support services – from global clinical trial and
specialty logistics to patient access and adherence. By offering
assistance at all stages of the product life cycle,
AmerisourceBergen enables manufacturers to stay focused on
developing life-saving therapies, while also having the confidence
that their developments are expertly commercialized and brought to
patients in need.
About AmerisourceBergen
AmerisourceBergen provides pharmaceutical products,
value-driving services and business solutions that improve access
to care. Tens of thousands of healthcare providers, veterinary
practices and livestock producers trust us as their partner in the
pharmaceutical supply chain. Global manufacturers depend on us for
services that drive commercial success for their products. Through
our daily work—and powered by our 22,000 associates—we are united
in our responsibility to create healthier futures.
AmerisourceBergen is ranked #10 on the Fortune 500, with more than
$175 billion in annual revenue. The company is headquartered in
Valley Forge, Pa. and has a presence in 50+ countries. Learn more
at amerisourcebergen.com.
1 “Key Statistics for Gastrointestinal Stromal Tumors.” American
Cancer Society,
www.cancer.org/cancer/gastrointestinal-stromal-tumor/about/key-statistics.html
2 “GIST Questions & Answers - Patient & Caregiver
Information.” The Life Raft Group, 7 Jan. 2020,
liferaftgroup.org/gist-faq/. 3 “GIST Questions & Answers -
Patient & Caregiver Information.” The Life Raft Group, 7 Jan.
2020, liferaftgroup.org/gist-faq/. 4 “Deciphera Pharmaceuticals
Announces U.S. Food and Drug Administration Acceptance of New Drug
Application and Priority Review for Ripretinib in Patients with
Advanced Gastrointestinal Stromal Tumors.” Deciphera
Pharmaceuticals, Inc., 12 Feb. 2020,
investors.deciphera.com/news-releases/news-release-details/deciphera-pharmaceuticals-announces-us-food-and-drug.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200526005069/en/
Francesca Gunning, AmerisourceBergen 610-727-7433 – Office
215-603-9264 – Mobile fgunning@AmerisourceBergen.com MaryKate
Dougherty, Tierney Communications 215-790-3094 – Office
mdougherty@tierneyagency.com
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Apr 2023 to Apr 2024